



We want to save patients with severe cancer and autoimmune diseases

Liselotte Larsson, VP Operations

Safe Harbour Statement

The following presentation may include predictions, estimates or other information that might be considered forward-looking. The statements regarding the surrounding world and future circumstances in this presentation reflect Cantargia's current thinking with respect to future events and financial performance. Prospective statements only express the assessments and assumptions the company makes at the time of the presentation. These statements are well-considered, but the audience should note that, as with all prospective assessments, they are associated with risks and uncertainties.

ASCO oral presentation of CANFOUR phase I data


June 2 at 08.00-11.00 in Category: Developmental Immunotherapy and Tumor Immunobiology

“Results from a first-in-man, open label, safety and tolerability trial of CAN04 (nidanilimab), a fully humanized monoclonal antibody against the novel antitumor target, IL1RAP, in patients with solid tumor malignancies”


Prof. Ahmad Awada, MD, Institut Jules Bordet, BE

Cantargia – opportunity to save lives and create value

- Potentially more effective treatments in clinically validated pathway
- First in class platform technology against novel target
- Right team and clear plan to position our projects and maximize value




Cantargia core – counteracting tumor inflammation



Clinical validation of inflammation pathway

CANTOS trial (n=10 061)

- Canakinumab anti IL-1 β (Novartis)
- Reduced lung cancer incidence by 67 % and death by 77 %.



Canakinumab phase 3 trials

(to be completed 2021/2022)

Adjuvant NSCLC (CANOPY-A) 1500 patients
After surgery, no mets, placebo control

First line (CANOPY-1) 627 patients
Untreated locally advanced/metastatic
Combination Pembro/Platinum doublet


Second line metastatic (CANOPY-2) 240 patients
Previously treated loc adv/metastatic
Combination Docetaxel

...and Gevokizumab trials in to start:


- Renal cell cancer
- Gastroesophageal cancer
- Colorectal cancer

Source: clinicaltrials.gov

CAN04 (nidanilimab) added value vs canakinumab



IL-1 signalling



Canakinumab

- Antibody directed against one of the two IL-1 ligands, IL-1β


CAN04 (nidanilimab)

Double mechanism



- Binds the signalling receptor and counteracts both ligands
- Induces killing via the immune system (ADCC)

.....Cantargia has patents on IL1RAP


CAN04 –Dual anticancer mechanism




Blocking IL-1 signaling




ADCC




NSCLC



IL1α



IL1β



Ctrl

CAN04 blocks tumor inflammation and stimulates direct killing of cancer cells

CAN04 – CANFOUR clinical trial


Phase I

- NSCLC, PDAC and colon cancer
- Good safety up to 10 mg/kg
- Significant effect on relevant biomarkers (IL-6, CRP)
- 9 patients had stable disease up to 6 months

Phase IIa

- FPI Jan 2019 – results early 2020
- NSCLC and PDAC
- Monotherapy
- Combination with standard therapy
 - NSCLC Cisplatin/Gemcitabine
 - Pancreatic cancer Gemcitabine/nab-paclitaxel
- Sites in Norway, Denmark, Holland and Belgium, Germany, Sweden and Austria (total 20 sites)


..and new complementary trial to open in USA




Details on www.clinicaltrials.gov

Extensive Biomarker program

Phase I



Phase II




Purposes:



- Generate clinical proof of concept
- Identification of patients most likely to respond.

IL1RAP found in several cancer forms with high medical need

Normal cell



Cancer cell



- Cantargia founded based on:
 - Discovery of IL1RAP on cancer cells
 - Antibodies against IL1RAP - antitumor effects
 - Patents on antibody therapy against IL1RAP
- Primary indications are NSCLC and pancreatic cancer
- Biomarker studies ongoing, identify patients most likely to respond
- Opportunity to expand development in additional cancer forms

Two major preclinical findings during 2018


- new opportunities

Synergistic effects with chemotherapy combination


- Stronger antitumor effects
- Counteracts chemotherapy toxicity

Binding to immune cells in tumor microenvironment

- Antimetastatic effects
- Counteract immune suppression




Targeting IL1RAP allows synergistic effects with Cisplatin/Gemcitabine



- CAN04 increases antitumor effects of platinum compounds (cisplatin, carboplatin, oxaliplatin)
- CAN04 counteracts toxicity from platinum compounds

CAN04 attacks several cell types in the tumor



CAN04 is relevant to several parts of cancer progression

Identification of additional opportunities

Findings from CANTOS trial (Novartis' canakinumab)

CANCER - decreased risk of death (high dose)

Lung cancer	77 %	P=0.0002	
Non-lung cancer	37 %	P=0.06	

INFLAMMATORY DISEASE - decreased incidence (all doses)


Arthritis	32%	p<0.0001	
Osteoarthritis	28%	P=0.0005	
Gout	53%	p<0.0001	
Cardiovascular	12%	P=0.02	

BIOMARKERS - levels reduction

CRP	26-41%	P<0.0001	
IL-6	25-43%	P<0.001	

IL1RAP platform to treat serious diseases

- Three different systems signal through IL1RAP
- These systems contribute to various inflammatory diseases
- Can be blocked by Cantargia's antibodies against IL1RAP



Cantargia partnership with Panorama Res Inc (Sunnyvale, CA)
Selection of clinical candidate 2019

Significant value inflection points

- ahead of CANFOUR results

2019

- US regulatory and clinical strategy
- ASCO oral presentation of phase I data
- Clinical progress and initial phase IIa results
- Preclinical progress (immuno-oncology effects, combinations etc)
- CANxx progress
- US clinical trial

2020

- Phase IIa results
- Phase Iia expansion

Production agreement with Patheon

- Complements the current agreement with Celonic AG (formerly Glycotope Biotechnology GmbH)
- Patheon will scale up the process to 2000 litres before next production campaign of clinical material.
- Patheon has manufacturing facilities in both Europe and USA

Strategic supply agreement in preparation for late stage development

Cantargia in brief

- Specialized in antibody therapy/immunology/oncology
- Lead antibody CAN04 (nidanilimab) in phase IIa clinical development, pathway clinically validated, data early 2020
- Platform around IL1RAP, lead candidate for autoimmunity and inflammatory disease in 2019
- Granted IP - therapeutic target IL1RAP and CAN04
- Strong management team with proven track record in clinical development and business development
- Listed on Nasdaq Stockholm
- Approximately 5000 shareholders incl strong long term investors
- Based in Lund, Sweden

Financial highlights

- Share price: 18.50 SEK (1.93 USD), May 16, 2019
- Market cap: 1347 MSEK (140 MUSD), May 16, 2019
- Cash: 167 MSEK (18.1 MUSD), Dec 31, 2018 + 106 MSEK (11.4 MUSD) from directed share issues

Current owners (April 30, 2019)

Sunstone	8.2%
Alecta	6.6%
1st AP fund	6.3%
Avanza Pension	5.8%
Öhman Bank S.A.	4.2%
4th AP fund	4.2%
SEB S.A.	4.2%
2nd AP fund	3.0%
Mats Invest AB	1.8%
Handelsbanken fonder	1.8%
Others	54.0%

Thank you for your attention!

www.cantargia.com